Prescriber Scope of Practice for Narcolepsy in Illinois

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients via telehealth, you’re probably asking: Can I legally prescribe stimulants and other controlled substances remotely? The short answer in 2026 is yes—but with significant caveats that vary by state.

Narcolepsy treatment relies heavily on Schedule II stimulants (Adderall, Ritalin), Schedule IV wakefulness agents (modafinil, armodafinil), and Schedule III sedatives like sodium oxybate (Xyrem). Under normal federal law (the Ryan Haight Act), prescribing any controlled substance via telemedicine requires at least one in-person medical evaluation. But we’re not operating under ‘normal’ rules right now.

Here’s the current reality: The DEA’s COVID-era telehealth flexibilities have been extended through December 31, 2026, allowing you to prescribe controlled substances—including narcolepsy medications—via telehealth without an initial in-person visit, as long as you meet standard prescribing requirements and comply with state law (www.hhs.gov).

But state laws add critical layers of complexity. Some states explicitly prohibit telehealth prescribing of Schedule II stimulants for non-psychiatric conditions (looking at you, Florida). Others restrict what PMHNPs can prescribe regardless of the visit format. And all of this could change when the DEA finally issues permanent telemedicine rules—likely sometime in 2025-2026.

Let’s break down what you need to know to practice compliantly and capitalize on the telehealth opportunity for narcolepsy care.

Understanding Federal DEA Rules: The Ryan Haight Act and COVID Waivers

The Baseline: Ryan Haight Act Requirements

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 established that prescribing controlled substances via the internet requires at least one in-person medical evaluation (www.law.cornell.edu). Limited exceptions existed pre-COVID for scenarios like VA/IHS patients, hospital-based care, or referrals from physicians who conducted in-person exams—but none that made pure telehealth narcolepsy practices feasible.

This meant that before 2020, if you wanted to prescribe Adderall or modafinil for a narcolepsy patient you’d never met in person, you were technically violating federal law.

The Game-Changer: COVID Telehealth Flexibilities

In March 2020, the DEA waived the in-person exam requirement to prevent care disruptions during the pandemic. This temporary policy allowed prescribers to initiate and continue controlled substance prescriptions via audio-visual telehealth (or even audio-only in some cases) without ever meeting the patient face-to-face.

When the federal Public Health Emergency ended in May 2023, the DEA didn’t pull the plug. Instead, recognizing that millions of patients (and thousands of telehealth practices) now depended on remote prescribing, they’ve issued four consecutive extensions. The latest, announced January 2, 2026, extends these flexibilities through the end of 2026 (www.hhs.gov).

What this means for narcolepsy providers: Through at least December 31, 2026, you can:

• Conduct initial evaluations via video (or in limited cases, phone)
• Diagnose narcolepsy based on clinical history, validated sleep scales (Epworth Sleepiness Scale), and coordination with sleep study facilities
• Prescribe Schedule II-V controlled substances including amphetamines, methylphenidate, modafinil, and sodium oxybate
• Continue ongoing medication management entirely via telehealth

The catch: You must still meet all other DEA requirements—proper licensure in the patient’s state, DEA registration for the appropriate schedules, legitimate medical purpose, usual course of practice, PDMP checks, and compliance with state-specific rules.

What’s Coming: Permanent DEA Telemedicine Rules

The DEA has been working on permanent regulations since 2022. Initial proposals in 2023 suggested requiring an in-person visit within 30 days of starting Schedule II stimulants—a restriction that would have severely limited telehealth narcolepsy care. After receiving over 38,000 public comments (mostly negative), the DEA pulled back and continued the temporary extensions while reconsidering their approach (www.dea.gov).

In January 2025, the DEA finalized two narrow exceptions—one for buprenorphine in opioid use disorder treatment, and one for VA patients—suggesting they’re willing to create condition-specific carve-outs (www.dea.gov). Narcolepsy advocates and sleep medicine societies are lobbying for similar treatment.

Provider strategy: Build your practice expecting eventual in-person requirements, but capitalize on the current flexibility. Consider hybrid models—partner with local sleep centers or primary care practices for periodic in-person visits, or plan to convert purely remote patients to hybrid care when regulations tighten.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where Can You Prescribe What?

Federal law sets the floor, but states often add restrictions. Here’s what matters for narcolepsy telehealth in the six most important markets:

Florida: The Most Restrictive

The problem: Florida explicitly prohibits prescribing Schedule II controlled substances via telehealth except for psychiatric disorders, inpatient care, hospice, or nursing home residents (www.leg.state.fl.us).

Narcolepsy is a neurological sleep disorder—not a psychiatric condition. This means you cannot prescribe Adderall, Ritalin, or other Schedule II stimulants for narcolepsy via pure telehealth in Florida, even under the current federal waiver.

Workarounds:

• Prescribe modafinil or armodafinil (Schedule IV)—these are allowed via telehealth
• Require at least one in-person visit before starting Schedule II stimulants
• Partner with Florida sleep centers or primary care practices for initial exams
• Focus on patients who can access local diagnostic services for sleep studies anyway

PMHNP limitations in Florida: Even worse for nurse practitioners—Florida limits APRNs to 7-day supplies of Schedule II medications unless they’re ‘psychiatric nurses’ treating mental health disorders (www.flsenate.gov). Since narcolepsy isn’t a mental illness, a Florida PMHNP can’t write ongoing stimulant prescriptions for narcolepsy—you’d need a supervising physician to handle refills.

The business case: Florida’s 22 million residents and shortage of sleep specialists create massive demand, but the regulatory barriers mean you’ll need physician involvement or limit your formulary. Many telehealth platforms operating in Florida use MDs exclusively for narcolepsy patients requiring stimulants.

New York: Following Federal Rules (For Now)

The good news: New York allows full practice authority for experienced PMHNPs (3,600+ hours) and recently aligned its controlled substance telehealth rules with federal law (www.nixonpeabody.com).

NY’s 2025 regulation requires an in-person exam before prescribing controlled substances unless you’re complying with federal DEA exceptions—which currently includes the COVID telehealth waiver (www.nixonpeabody.com). When the DEA waiver expires, NY will enforce its in-person requirement unless you qualify under one of the other exceptions (e.g., recent exam by a referring provider, covering for another practitioner’s established patient).

What this means: Both psychiatrists and independent PMHNPs can currently treat narcolepsy entirely via telehealth in New York. When DEA rules change, you’ll need to adapt—but NY’s framework gives you multiple compliance pathways.

Requirements:

• State medical or APRN license
• DEA registration
• Registration with NY’s I-STOP prescription monitoring program (mandatory PDMP checks)
• Electronic prescribing (required for all controlled substances)

The opportunity: New York’s 19 million residents, strong insurance coverage for telehealth, and NP-friendly laws make it one of the best markets for expanding narcolepsy services.

Texas: Physician Authority Only for Schedule II

The restriction: Texas APRNs and PAs cannot prescribe Schedule II controlled substances in outpatient settings—period. The only exceptions are hospital inpatients (24+ hour stays) or hospice patients (www.tmb.state.tx.us).

This means a Texas PMHNP cannot write prescriptions for amphetamines or methylphenidate for narcolepsy patients—even with physician supervision and even via telehealth. The supervising physician must write those prescriptions directly.

Good news: Texas allows Schedule III-V prescribing by APRNs under physician delegation, so modafinil (Schedule IV) is fair game for PMHNPs.

Telehealth rules: Texas permits establishing patient relationships via two-way audio-visual communication (video required—phone-only won’t work for controlled substances). No state-specific barrier to telehealth prescribing of narcolepsy meds beyond the APRN Schedule II restriction (www.cchpca.org).

The business model: If you’re an PMHNP targeting Texas, plan to use modafinil/armodafinil exclusively or partner with MDs/DOs to prescribe stimulants. If you’re a psychiatrist, Texas is wide open—30 million residents with significant rural/underserved areas desperate for specialty mental health and sleep care.

California: NP Independence Expanding Access

The evolution: California implemented full practice authority for nurse practitioners via AB 890, with experienced PMHNPs (4,600+ hours) able to practice independently starting in 2023 (rxagent.co).

Schedule II prescribing: California NPs must complete specific pharmacology training on controlled substances and obtain furnishing authority from the Board of Registered Nursing before prescribing Schedule II medications (rn.ca.gov). Once certified, independent PMHNPs can prescribe Adderall, Ritalin, and other narcolepsy stimulants.

Telehealth: No state restrictions beyond federal law. California recognizes telehealth exams as equivalent to in-person if they meet the standard of care.

Critical requirement: Mandatory PDMP checks via California’s CURES system before prescribing Schedule II-IV controlled substances, with re-checks at least every 4 months for ongoing therapy.

The opportunity: California’s 39 million residents, shortage of sleep specialists, and NP-friendly regulations make it prime territory for narcolepsy telehealth expansion—whether you’re a psychiatrist or an experienced PMHNP.

Pennsylvania: Collaboration Required, But Workable

PMHNP scope: Pennsylvania requires all NPs (CRNPs) to have physician collaborative agreements. NPs can prescribe Schedule II-V controlled substances if the collaborating physician approves and it’s outlined in the agreement.

Limits: CRNPs can prescribe up to 30 days of Schedule II medications initially; continuation requires physician consultation and documentation. Schedule III-IV limited to 90-day supplies.

Telehealth: No state-specific barriers to controlled substance prescribing via telehealth—Pennsylvania defers to federal DEA rules. Recent legislation even authorized telehealth initiation of buprenorphine for opioid treatment (with 14-day in-person follow-up), signaling openness to remote prescribing (www.cchpca.org).

The model: PMHNPs treating narcolepsy in Pennsylvania need engaged collaborating physicians willing to co-manage patients and authorize ongoing Schedule II therapy. This adds administrative overhead but doesn’t prohibit the practice.

Illinois: Full Practice Authority with Minor Caveats

NP independence: Illinois grants full practice authority to NPs after 4,000 hours of collaborative practice plus 250 hours of specialty continuing education (rxagent.co). Once achieved, PMHNPs practice independently including prescribing Schedule II-V controlled substances.

Consultation requirement: Illinois law requires NPs with full practice authority to maintain a ‘consultation relationship’ with a physician when prescribing benzodiazepines or opioids. Stimulants aren’t explicitly included in this requirement, meaning independent PMHNPs likely can prescribe Adderall and other Schedule II stimulants for narcolepsy without physician oversight.

Telehealth: No state restrictions. Illinois was an early adopter of telehealth parity and made COVID-era expansions permanent in 2021.

Requirements:

• Electronic prescribing mandatory for all controlled substances (since Jan 2023)
• Illinois Prescription Monitoring Program (ILPMP) checks required before prescribing

The opportunity: Illinois offers one of the most favorable environments for PMHNP-led narcolepsy telehealth—experienced NPs can operate essentially like psychiatrists, just with the consultation relationship backstop for highest-risk medications.

Psychiatrist vs PMHNP: Scope and Authority for Narcolepsy

What Psychiatrists Can Do

Authority: Full diagnostic and prescriptive authority in all 50 states for narcolepsy and any other medical condition within your competency. As long as you hold:

• State medical license where the patient is located
• DEA registration covering Schedule II-V controlled substances
• Compliance with state PDMP requirements

You can diagnose narcolepsy, order necessary tests (polysomnography, MSLT), and prescribe any medication—stimulants, modafinil, sodium oxybate, tricyclic antidepressants for cataplexy, you name it.

Legitimate use requirements: Some states explicitly list approved indications for Schedule II stimulants. Florida law, for example, permits amphetamine prescribing only for narcolepsy, ADHD, drug-induced brain dysfunction, epilepsy, or refractory depression (www.flsenate.gov). Narcolepsy is on the approved list, so you’re covered—but this illustrates the importance of diagnosing appropriately and documenting clinical rationale.

The diagnostic challenge: Confirming narcolepsy typically requires polysomnography and Multiple Sleep Latency Testing (MSLT) performed in a sleep lab—inherently in-person procedures. As a telepsychiatrist, you’ll need to:

• Establish referral relationships with sleep centers in your patients’ geographic areas
• Coordinate testing and review results before finalizing diagnosis
• Be prepared to manage empirically in some cases (excessive daytime sleepiness with high Epworth scores might justify a modafinil trial while awaiting formal testing)

What PMHNPs Can Do (State-Dependent)

The reality: PMHNPs have varying authority depending on where they practice and their career stage.

Full authority states (experienced NPs):

• California: Independent practice with Schedule II authority after training (rn.ca.gov)
• New York: Independent practice with full prescribing after 3,600 hours
• Illinois: Independent practice with Schedule II authority after 4,000 hours + education

In these states, an experienced PMHNP can essentially practice like a psychiatrist for narcolepsy—diagnosing, prescribing stimulants and other controlled medications, managing ongoing care.

Restricted states (major limitations):

• Texas: Cannot prescribe Schedule II at all in outpatient settings (www.tmb.state.tx.us)
• Florida: 7-day Schedule II limit for non-psychiatric conditions (www.flsenate.gov)
• Pennsylvania: 30-day Schedule II limit, physician consultation required for continuation

Scope of practice considerations: Even in states where PMHNPs can prescribe narcolepsy medications, some questions remain:

• Is narcolepsy within a psychiatric NP’s scope, or is it purely neurological?
• Will malpractice insurance cover narcolepsy treatment?
• Do you have the training and competency to manage this condition?

The reality: Many psychiatric medications overlap with narcolepsy treatment (stimulants for EDS, tricyclics for cataplexy, SSRIs/SNRIs for REM sleep symptoms). A PMHNP comfortable managing ADHD with stimulants has much of the pharmacological expertise needed for narcolepsy. The key differences are:

• Understanding sleep physiology and narcolepsy pathophysiology
• Coordinating diagnostic testing with sleep specialists
• Managing narcolepsy-specific medications like sodium oxybate (Xyrem)—a Schedule III medication with FDA-mandated REMS program requiring special enrollment

Practical approach: PMHNPs treating narcolepsy should pursue additional education in sleep medicine, maintain consultation relationships with sleep neurologists for complex cases, and ensure their malpractice coverage includes sleep disorder management. Many do this successfully—the condition has enough psychiatric overlap to be defensible within PMHNP scope, especially given the shortage of sleep specialists.

Special Medication Considerations for Narcolepsy

Schedule II Stimulants (Amphetamines, Methylphenidate)

What works: These remain first-line for many narcolepsy patients with excessive daytime sleepiness.

The regulatory reality:

• Highest level of DEA scrutiny
• State PDMP checks required before every prescription in most jurisdictions
• Some states limit quantities (30-day supply, 7-day in FL for certain prescribers)
• E-prescribing mandatory in most states
• Abuse potential requires careful patient selection and monitoring

Telehealth implications: Under current DEA waivers, you can initiate these remotely. When rules change, expect to need in-person visits—either initial or periodic (likely every 3-6 months).

Modafinil/Armodafinil (Schedule IV)

The telehealth-friendly option: As Schedule IV medications, these face fewer restrictions:

• Easier to prescribe via telehealth (even Florida allows it)
• PMHNPs in restrictive states like Texas can prescribe them
• Less regulatory scrutiny than Schedule II stimulants
• Still require PDMP checks and DEA registration

Clinical effectiveness: Often first-line for narcolepsy EDS. Many patients respond well, making this a practical choice for telehealth practices navigating regulatory complexity.

Strategy: Some providers use modafinil as initial therapy via telehealth, then transition to stimulants if needed after establishing in-person relationship or when patient can access local care.

Sodium Oxybate (Xyrem, Xywav) – Schedule III

The complication: These medications treat cataplexy and are highly effective, but they come with an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) program.

What this means:

• You must enroll in the Xyrem/Xywav REMS to prescribe
• Additional documentation and patient education required
• Central pharmacy dispensing only (can’t fill at local pharmacy)
• More administrative burden than typical prescriptions

Telehealth fit: The REMS requirements don’t prohibit telehealth—you can enroll, evaluate patients remotely, and prescribe. But the added complexity means many telehealth providers focus on wakefulness medications and refer complex cataplexy cases to in-person specialists.

Combination Therapy

Reality of narcolepsy care: Many patients need multiple medications—a stimulant or modafinil for daytime sleepiness, plus an antidepressant (SSRI, SNRI, or tricyclic) for cataplexy or REM sleep symptoms.

Telehealth advantage: Psychiatrists and PMHNPs are already expert in antidepressant management. Adding stimulant/modafinil expertise creates a comprehensive narcolepsy practice model that sleep neurologists (who may be less comfortable with psychiatric medications) can’t match.

Economics: Why Narcolepsy Telehealth Makes Business Sense

The Patient Acquisition Reality

Let’s be honest about the economics of growing a specialty practice. If you’re trying to build a narcolepsy patient panel through traditional marketing:

DIY marketing costs (real numbers):

• SEO: 6-12 months of consistent investment ($2,000-5,000/month) before meaningful patient flow
• Google Ads: Mental health and sleep keywords cost $15-40+ per click; realistic cost per booked patient is $200-400+ after accounting for click-to-conversion rates
• Psychology Today/Zocdoc: Monthly directory fees ($50-300) PLUS per-booking charges ($35-100) PLUS you compete with hundreds of other providers on the same platform
• Agency/consultant fees: $3,000-10,000/month if you outsource marketing
• Staff time: Handling and qualifying leads, managing no-shows from cold traffic
• Failed campaigns: Money spent testing channels that don’t work

True patient acquisition cost: When you add up ALL expenses—ad spend, agency fees, staff time, failed experiments, no-shows—acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ per patient. Some specialties see costs exceed $1,000 per acquired patient.

And here’s the killer: you’re paying these costs upfront with no guarantee of results. Your marketing budget gets spent whether patients book or not.

The Platform Model: Guaranteed ROI

Platforms like Klarity Health flip the economics:

Pay-per-appointment model:

• Standard listing fee per new patient lead (similar to Zocdoc’s per-booking charge)
• But unlike Zocdoc, patients are pre-qualified and matched to your specialty and availability
• No monthly subscription fees eating into your revenue
• No wasted ad spend on clicks that don’t convert
• No hiring agencies and hoping they deliver
• Built-in telehealth infrastructure (no separate platform costs like Doxy.me or SimplePractice)

The value proposition: Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay only when a qualified patient actually books with you. That’s guaranteed ROI vs gambling on marketing channels you may not have expertise to optimize.

Both insurance and cash-pay patients: Platforms can deliver patient flow across payment types, giving you revenue diversification that takes years to build organically.

You control your schedule: Only pay when you see patients. Take a month off? No patients, no charges. Scale up? More patients, more revenue—with patient acquisition cost baked in at a predictable rate.

The Reality for Narcolepsy Specialists

Market dynamics:

• Narcolepsy affects ~200,000 Americans but often goes undiagnosed for 8-15 years
• Patients desperately need specialists who understand the condition
• Most sleep centers have 3-6 month wait times
• Primary care providers often miss the diagnosis or aren’t comfortable managing controlled substances long-term

Your competitive advantage: As a psychiatrist or PMHNP with controlled substance prescribing authority, you can offer what many neurologists can’t—comprehensive medication management via accessible telehealth.

Revenue potential: Narcolepsy is a chronic condition requiring ongoing medication management, typically:

• Initial evaluation + diagnostic coordination: $200-400
• Monthly medication management visits (15-30 min): $100-200
• Annual revenue per patient: $1,200-2,400

With a panel of just 20-30 active narcolepsy patients, you’re generating $25,000-75,000 in annual revenue from this specialty alone—alongside your broader psychiatric practice.

Platform leverage: Instead of spending months building SEO and thousands on ads to attract those 20-30 patients, a platform delivers pre-qualified leads. You focus on what you do best—clinical care—while the platform handles patient acquisition.

Compliance and Risk Management Essentials

Regardless of your state or practice model, these are non-negotiable:

1. PDMP Checks

Every state requires checking prescription drug monitoring programs before prescribing controlled substances. Make this part of your workflow:

• Check before initial prescription
• Check periodically during ongoing care (every 3-6 months minimum; some states mandate every prescription)
• Document the check in your chart note

2. Thorough Documentation

Telehealth controlled substance prescribing gets scrutinized. Document:

• Clinical rationale for narcolepsy diagnosis (symptoms, duration, impact on function)
• Results of sleep studies or explanation of why empiric trial is appropriate
• Discussion of risks/benefits of controlled medications
• Patient consent for telehealth treatment
• Periodic reassessment of ongoing need and monitoring for misuse

3. E-Prescribing

Most states now mandate electronic prescribing for controlled substances. Use a HIPAA-compliant platform with two-factor authentication meeting DEA requirements.

4. Standard of Care

Just because you’re practicing via video doesn’t mean you can cut corners:

• Conduct thorough initial evaluation (medical history, sleep history, mental status exam, review of systems)
• Use validated tools (Epworth Sleepiness Scale, sleep logs)
• Screen for comorbidities (depression, anxiety, substance use)
• Have emergency protocols for adverse events
• Coordinate with local providers when in-person care is needed

5. Malpractice Coverage

Verify your policy covers:

• Telehealth practice across the states where you’re licensed
• Sleep disorder management (if you’re pivoting from pure psychiatry)
• Controlled substance prescribing

6. DEA Registration

You need a DEA number for each state where you prescribe, with a physical address in that state. Multi-state practitioners often use their home address or the telehealth company’s registered agent address in each state.

7. Informed Consent

Document patient understanding of:

• Telehealth limitations (can’t perform physical sleep studies remotely)
• Their responsibility to obtain required in-person testing
• Risks of controlled medications
• Your prescribing policies (refill schedules, no early refills, consequences of misuse)

How to Start (or Expand) Your Narcolepsy Telehealth Practice

For Psychiatrists

You have maximum flexibility. The question is how to efficiently build patient volume:

Option 1: DIY Marketing

• Good if: You have marketing expertise, budget for 6-12 months of losses, and patience
• Reality: Most psychiatrists don’t have time to become SEO/PPC experts while maintaining full clinical schedules
• Costs: $3,000-10,000/month in ad spend + agency fees with no guaranteed results

Option 2: Join a Platform (Klarity Health Model)

• Good if: You want predictable patient acquisition costs and pre-qualified leads
• Reality: You pay per patient but eliminate upfront marketing risk
• Built-in telehealth infrastructure, credentialing support, both insurance and cash patients
• Focus on clinical care, not marketing optimization

Multi-state strategy: Get licensed in 3-5 high-population states with favorable telehealth laws (California, New York, Illinois, Texas if you’re comfortable with the landscape, Pennsylvania). This dramatically expands your addressable market.

For PMHNPs

Your path depends on your state and experience level:

If you’re in a full-authority state (CA, NY, IL) with qualifying experience:

• You can practice essentially like a psychiatrist for narcolepsy
• Same patient acquisition options (DIY vs platform)
• Emphasize your psychiatric medication expertise in positioning—many narcolepsy patients have comorbid depression/anxiety

If you’re in a restricted state (TX, FL, PA):

• Partner with a collaborating physician willing to co-manage narcolepsy patients
• Focus on modafinil/armodafinil prescribing where permitted
• Position yourself as the clinical manager with MD providing stimulant prescriptions
• OR: Get licensed in nearby full-authority states and practice telehealth from there

Gain specialized expertise:

• Take CME courses in sleep medicine
• Consider ANCC certification in Psychiatric-Mental Health (if you haven’t already)
• Join professional organizations (American Academy of Sleep Medicine offers membership to non-physicians)
• Develop consultation relationships with sleep neurologists for complex cases

Building Your Clinical Model

Hybrid approach (recommended):

1. Start with telehealth evaluation and modafinil/armodafinil trials
2. Coordinate sleep studies with local facilities in patient’s area
3. Once diagnosis confirmed, transition to stimulants if needed
4. Schedule monthly telehealth follow-ups initially, then quarterly once stable
5. Require annual in-person visit with local provider (could be PCP) to stay ahead of likely future DEA rules

Specialist positioning: Don’t try to be a general sleep specialist. Position as:

• ‘Psychiatric provider specializing in narcolepsy medication management’
• Emphasize expertise in stimulants, managing comorbid psychiatric conditions
• Refer complex cases (children, suspected secondary narcolepsy) to sleep neurologists
• Own the medication management niche

FAQ: Narcolepsy Prescribing via Telehealth

Can I diagnose narcolepsy without an in-person exam?

Clinically, yes—narcolepsy diagnosis is based on history, symptom pattern, and sleep study results (which must be done in-person at a sleep center). Legally, telehealth exams are equivalent to in-person in all states for diagnostic purposes. The challenge is coordinating the required polysomnography and MSLT, which cannot be done remotely.

What happens when DEA’s COVID waiver expires?

The current extension runs through December 31, 2026. When permanent rules are finalized, they’ll likely require either: (1) initial in-person exam before prescribing Schedule II stimulants, or (2) 30-day supply limits via telehealth before in-person visit, or (3) condition-specific exceptions for established diagnoses. Monitor DEA announcements and plan for hybrid care models.

Can I treat narcolepsy patients in multiple states?

Yes, if you’re licensed and have DEA registration in each

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206